bizarre 'polymyositis', with bizarre disruptive changes in enzyme distribution in the muscle fibres.

**National inquiry into convulsive disorders in childhood.** Euan M. Ross (introduced by Dr. Peter M. Dunn) (Department of Child Health, University of Bristol). A detailed study is being made of the incidence, nature, and pattern of convulsive disorders reported in the 15,000 surviving children born in England, Scotland, and Wales during the week 3–9 March 1958, and originally included in the Perinatal Mortality Study. 89% of these children were traced and studied as the National Child Development Study (1958 cohort).

As a result of comprehensive medical, social, and educational studies made when the children were aged 7 and repeated at age 11, it was possible to select 1100 children who had been reported as having had one or more convulsions, fants, or breath-holding episodes. From an exhaustive study of individual records it was possible to identify 347 children who fulfilled one or more of the following: (1) History of anticonvulsant medication. (2) Had had an EEG. (3) Regarded by a doctor as being 'epileptic'. (4) Had one or more definite seizures after age 5. (5) Had had three definite seizures at some time. (6) Teacher reported a seizure at school. (7) One or more seizures reported but also attends a special school.

Precoded questionnaires were sent to both the practitioners and consultants and, in certain cases, local authority doctors, who had looked after these children. To date there has been a 95% reply rate. In 98 children (6.3 per 1000) a doctor has at some stage regarded the child as being 'epileptic'. Only 32 children however, had had one or more fits since age 8 years (2 per 1000). Only 2 children appeared to have uncomplicated petit mal though a further 9 had mixed petit and grand mal. Patterns of drug administration were briefly described.

**Reference**


**Substrate induction of galactokinase in cultured fibroblasts from subjects heterozygous and homozygous for galactokinase deficiency.** F. Zacchello, P. F. Benson, P. Croll, F. Giannelli, and T. P. Mann (Paediatric Research Unit, Guy's Hospital Medical School, London S.E.1). Skin fibroblasts from a patient with galactokinase deficiency (Cook, Don, and Mann, 1971), the parents, and 4 controls were cultured in minimum essential Eagle's medium containing 10% human serum, either without or with galactose (5 or 15 mg/100 ml culture medium). Fibroblasts were harvested and assayed for galactokinase activity at intervals during a 15-day period, during which time the cells were trypsinized approximately every 7 days and the medium was changed every 3 days.

Mean galactokinase activity for normal fibroblasts was 6.18 units (n moles of galactose 1-phosphate formed/hr per mg fibroblast protein) without galactose in the medium. In the presence of galactose, activity was induced by the 3rd day, reached a maximum by the 6th day, and remained at the induced level until the 15th day. Mean activities were 9.45 units (with galactose 5 mg/100 ml) and 9.97 units (with galactose 15 mg/100 ml).

The patient with galactokinase deficiency had activities of 0.06 and 0.38 units without and with galactose in the medium (15 mg/100 ml), respectively. The father had a mean galactokinase activity of 3.20 units (51.8% of control) and the mother 2.68 units (43.4% of control). Mean activities in the presence of galactose (15 mg/100 ml) were: father 4.10 units (43.8% of control), mother 3.00 units (32.0% of control). Fibroblast galactokinase thus has properties both of a constitutive enzyme (since it is present in cells cultured in a medium without substrate) and of a substrate inducible enzyme. Galactokinase activity in heterozygous cells was intermediate between that of cells that were homozygous normal and those that were homozygous for galactokinase deficiency. Both in the induced and uninduced states, galactokinase activities were higher in the father (43.8% and 51.8% of control values respectively) than in the mother (32.0% and 43.4% of control values respectively).

**Reference**


**Plasma levels of cystine in homocystinuria.** I. B. Sardharwalla and B. Fowler (Willink Biochemical Genetics Laboratory, Royal Manchester Children's Hospital, Pendlebury, Manchester). In homocystinuria plasma levels of cyst(e)ine are low; one explanation for this finding is the lack of methionine conversion to cysteine. It is probable that there is a different and perhaps more significant reason for the reduced concentrations of cyst(e)ine. In this paper results of two studies are presented to expound the latter view.

In the first, a 7-year-old pyridoxine-resistant patient was given (1) low methionine diet followed by (2) high methionine diet (by adding l-methionine to the basic diet) to which (3) betaine hydrochloride was then added. Throughout the study, dietary cystine was kept constant. Measurements of sulphur amino acids in the plasma and urine were performed by ion exchange chromatography, the column effluent being simultaneously monitored with ninhydrin and iodoplatinate analytical systems. The results showed that (1) there was a reciprocal relation between the plasma levels of homocyst(e)ine and cyst(e)ine, and (2) cyst(e)ine was increased in spite of very high levels of methionine during betaine therapy.

In the second study, cystine loads were given to a 21-year-old pyridoxine-resistant patient (1) before and (2) during betaine therapy while the patient was on a constant normal diet. The result showed that on a fixed normal diet plasma levels of homocysteine-cysteine-disulphide increased significantly and there was a
National inquiry into convulsive disorders in childhood.

E M Ross

Arch Dis Child 1972 47: 150
doi: 10.1136/adc.47.251.150

Updated information and services can be found at:
http://adc.bmj.com/content/47/251/150.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/